Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety and PK of Nangibotide in Healthy Volunteers
NCT03463044Phase 1Completed
- Sponsor
- Inotrem
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nangibotide in septic shock (9 arms), sponsored by Inotrem. Primary endpoint: Number of Subjects Experiencing Treatment Emergent Adverse Events. Started Apr 2016; status: completed.
02
Drugs
nangibotide
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03463044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463044.